NASDAQ$CRON
Cronos Group Inc · Q2 2020 earnings
Q2 2020 earnings · · Investor relations
Briefing
Cronos Group's Q2 2020 results were announced, marking entry into the Israeli medical cannabis market and progress across global operations amidst industry shifts.
Cronos Group reported a net revenue increase of $2.2 million compared to Q2 2019, driven by growth in the Canadian adult-use market and the inclusion of the Redwood acquisition. However, the company experienced a decrease in gross profit due to increased cost of sales and an inventory write-down.
- Net revenue increased by $2.2 million year-over-year, driven by Canadian cannabis market growth and cannabis vaporizer sales.
- Cronos Israel commenced sales of PEACE NATURALS™ branded cannabis to the Israeli medical market.
- Gross profit decreased due to higher cost of sales and a $3.1 million inventory write-down.
- The company expanded distribution of cannabis vaporizer devices in the Canadian adult-use market.
Headline financials
Revenue & EPS history
Cronos · Revenue · Quarterly
$9.88M
Revenue by segment
Cronos · $9.88M total across 2 segments · Q2 2020
- Israel and Other$7.71M—78.0%
- Canada$2.17M—22.0%
Forward guidance
Due to ongoing developments and uncertainty resulting from the COVID-19 pandemic, it has been difficult to predict the continuing impact that COVID-19 will have on the Company. The Company anticipates further inventory write-downs due to pricing pressures in the marketplace, as well as increased marginal production costs at the Peace Naturals Campus.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q2 2020
-1.8%
Avg return
Earnings day
-1.4%
Avg return
5 days after
+3.8%
Avg return
30 days after
34%
13 / 38 earnings
Positive
+35.6%
Q3 2020
Best reaction
-19.2%
Q2 2020
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +7.5% | +3.1% | +7.5% | |
| Q4 2025 | -3.6% | -6.1% | -9.7% | |
| Q3 2025 | +0.4% | +2.9% | +1.6% | |
| Q1 2025 | +8.2% | +10.3% | +7.0% | |
| Q4 2024 | +8.1% | +9.2% | -3.2% | |
| Q3 2024 | +10.2% | +2.0% | -0.5% | |
| Q2 2024 | -0.9% | +5.0% | -3.6% | |
| Q1 2024 | +7.4% | +13.6% | -5.8% | |
| Q4 2023 | -10.6% | -12.8% | +15.5% | |
| Q3 2023 | +4.2% | +6.3% | +11.1% | |
| Q2 2023 | -3.8% | -5.5% | +13.7% | |
| Q1 2023 | -5.5% | -13.1% | -14.6% | |
| Q4 2022 | +1.0% | +1.0% | -10.0% | |
| Q3 2022 | -10.1% | -1.0% | -6.2% | |
| Q2 2022 | -15.4% | -11.5% | -14.5% | |
| Q1 2022 | +5.3% | +15.5% | -0.4% | |
| Q4 2021 | -1.4% | -10.9% | +8.7% | |
| Q3 2021 | -11.1% | -12.1% | -4.7% | |
| Q2 2021 | -2.6% | -6.6% | -12.3% | |
| Q1 2021 | -4.3% | -6.0% | +13.0% | |
| Q4 2020 | +2.2% | -4.4% | -13.9% | |
| Q3 2020 | +35.6% | +31.2% | +55.8% | |
| Q2 2020 | -19.2% | -20.5% | -22.8% | |
| Q1 2020 | -5.7% | -13.4% | +18.1% | |
| Q4 2019 | -9.9% | +3.0% | +7.6% | |
| Q3 2019 | -10.1% | -22.3% | -9.7% | |
| Q2 2019 | -7.4% | -3.5% | -17.3% | |
| Q1 2019 | -0.4% | -1.4% | +3.1% | |
| Q4 2018 | -11.2% | -10.2% | -19.5% | |
| Q3 2018 | -3.9% | +1.3% | +34.7% | |
| Q2 2018 | +9.4% | +12.2% | +73.4% | |
| Q4 2017 | -8.5% | +4.1% | +18.1% | |
| Q1 2018 | -7.9% | -5.0% | +5.6% | |
| Q3 2017 | -7.2% | — | — | |
| Q2 2017 | +1.3% | — | — | |
| Q1 2017 | -5.1% | — | — | |
| Q4 2016 | -0.9% | — | — | |
| Q3 2016 | -1.6% | — | — | |
| Q2 2016 | — | — | — | |
| Q1 2016 | — | — | — | |
| Q4 2015 | — | — | — | |
| Q3 2015 | — | — | — | |
| Q2 2015 | — | — | — | |
| Q1 2015 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro